Surface Oncology
Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights.
Market cap
$65.1m
Enterprise value
$18m
Share price
$1.07 SURF
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
F-Prime(exited)
Atlas Venture(exited)
Lilly Ventures(exited)
NEA(exited)
Eight Roads Ventures(exited)
K2 HealthVentures(exited)
Novartis Institutes(exited)
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 363 % | (74 %) | 721 % | (98 %) | 1016 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (351 %) | (13 %) | (373 %) | 49 % | (2829 %) | (206 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (354 %) | (11 %) | (357 %) | 47 % | (2921 %) | (212 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 373 % | 88 % | 339 % | 33 % | 1994 % | 223 % |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.